Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Jade Biosciences, Inc.NASDAQ: JBIO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization of $9K in Q1 FY2026
Q1 FY2026 depreciation & amortization was $9K. Trailing-twelve-month depreciation & amortization was $31K. Over 3 fiscal years it compounded at -27.4% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $9K or moves back toward the trailing-twelve-month quarterly average of $7.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 26K USD
- Year-over-year change
- -90.8%
- 4-year CAGR
- +14.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26K | -90.8% |
| FY2024 | 2024-12-31 | 282K | +193.8% |
| FY2023 | 2023-12-31 | 96K | +41.2% |
| FY2022 | 2022-12-31 | 68K | +353.3% |
| FY2021 | 2021-12-31 | 15K | — |
Depreciation & Amortization vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's LTM Mar 2026 depreciation & amortization of $31K is the 7th largest of the 9 companies compared; the peer median is $590K.
- Over three fiscal years its annual growth of -27.4% compares with a peer median of -0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.08M | +114.9% | +496.0% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $2.42M | +1.1% | — | — |
| LTM Mar 2026 | $1.65M | -23.4% | +19.6% | — | |
| LTM Jun 2026 | $652K | +130.4% | — | — | |
| LTM Mar 2026 | $528K | -25.9% | -17.1% | 6.3% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $328K | +19.3% | -0.6% | — |
| LTM Mar 2026 | $31K | — | -27.4% | — | |
| LTM Mar 2026 | $1.88K | -89.0% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | -5.7% | — | |
| Peer median (excluding JBIO) | $590K | -11.1% | -0.6% | 6.3% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (6.51M) | 7.76M | 9.8M | (11.17M) | (8.2M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 609K | 1.37M | (164K) | (2.17M) | 361K |
| Other Working Capital | (7.12M) | 6.39M | 9.96M | (9M) | (8.56M) |
| Other Non-Cash Items | 2.06M | 4.57M | 8.85M | 9.32M | 40.89M |
| Operating Cash Flow | (27.4M) | (39.12M) | (56.78M) | (71.2M) | (94.69M) |
| Capital Expenditures | (181K) | (195K) | (142K) | 0 | (196K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (113.25M) | (147.62M) | (123.98M) | (19.68M) | (261.19M) |
| Sales of Investments | 0 | 154.74M | 136M | 75.71M | 14.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (31K) |
| Investing Cash Flow | (113.43M) | 6.93M | 11.88M | 56.03M | (247.01M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.46M | 396K | 46M | 25.43M | 360.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 156K |
| Financing Cash Flow | 190.46M | 396K | 46M | 25.43M | 360.77M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (52.82M) |
| Net Change in Cash | 49.62M | (31.8M) | 1.09M | 10.26M | 54.69M |
| Free Cash Flow | (27.58M) | (39.32M) | (56.92M) | (71.2M) | (94.89M) |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.